QIP 2017

Disclaimer – Important

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED IN THE UNITED STATES. THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NATCO PHARMA LIMITED (THE “COMPANY”) TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009, AS AMENDED (THE “SEBI REGULATIONS”).

Please read this notice carefully – it applies to all persons who view this site.

The placement and distribution of this Placement Document, dated December 14, 2017 (this “Placement Document”) is being done in reliance on Chapter VIII of the SEBI Regulations and Section 42 of the Companies Act, 2013.

The materials placed herein (the “Materials”) are so placed pursuant to the SEBI Regulations and are not intended to nor constitute an invitation to subscribe or a solicitation to offer to subscribe to the securities referred therein. Unless a pre-numbered Placement Document accompanied by an application form is addressed to a specific person inviting such person to make a bid through such application form, no offer and/or invitation of offer shall be deemed to have been made.

Unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended that any offering of securities by the Company would be made directly or indirectly, in or into, the United States, except pursuant to an exemption from registration as described below.

The securities being referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, or any U.S. state securities laws. Accordingly, subject to certain exceptions, such securities may not be offered, sold or otherwise transferred in or into the United States. The information and document contained behind these screens should not be viewed by any person resident or physically located in the United States.

The placement referred to herein is being made in reliance upon the SEBI Regulations and Section 42 of the Companies Act, 2013 and the rules made thereunder. This Placement Document is personal to each prospective investor and does not constitute an offer or invitation or solicitation of an offer to the public or any other person or class of investors within or outside India other than qualified institutional buyers, as defined in the SEBI Regulations. This Placement Document has not been and will not be registered as a prospectus with the Registrar of Companies in India, will not be circulated or distributed to the public in India or any other jurisdiction, and will not constitute a public offer in India or any other jurisdiction.

If you are not permitted to view the Materials on this website or are in any doubt as to whether you are permitted to view these Materials, please exit this webpage.

By accessing this webpage, you represent that at the time of access, you are located within India.

Natco Pharma Limited – Placement Document – 2017